Growth Factor Imaging

生长因子成像

• 批准号: 7291939
• 负责人: peter L choyke
• 金额: --
• 依托单位: DIVISION OF BASIC SCIENCES - NCI
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7291939
• 关键词: Growth; Factor; Imaging

Angiogenesis is regulated by several growth factors that lead to highly permeable blood vessels. This property of angiogenic vessels can be exploited with dynamic enhanced MRI imaging in the clinic and in animal studies. Macromolecular contrast agents may be able to measure angiogenesis more accurately and thus are a topic of interest to the MIP. We have developed dendrimer based molecules of varying molecular weight to measure tumor permeability and renal excretion. Other growth factors can also be imaged. Herceptin is a successful clinical agent, both in monotherapy and in combination therapy, in the fight against breast cancer. However, not all patients will benefit from this therapy. In conjunction with Dr. Martin Brechbiel we have developed a 111In labeled Herceptin Scan that enables the visualization of the distribution of HER2/neu receptors in the body and within tumors. This agent, which has been thoroughly evaluated in mice, has received preliminary approval for introduction into man in a Phase 0 study. In collaboration with the DDG we are manufacturing this agent for use in human trials in the Clinical Center to assess the biodistribution of Herceptin and monitor response. This study will serve as a basis for estimating dosimetry for future trials using radioimmunotherapy with alpha-emitters chelated to Herceptin, particularly in metastatic disease localized to the peritoneum.

血管生成受到几种导致高度渗透血管的生长因子的调节。在诊所和动物研究中，可以通过动态增强的MRI成像来利用血管生成的这种特性。大分子对比剂可能能够更准确地测量血管生成，因此是MIP感兴趣的话题。我们已经开发了不同分子量的基于树枝状聚合物的分子，以测量肿瘤的渗透性和肾脏排泄。其他增长因素也可以成像。赫赛汀是一种成功的临床药物，无论是单一疗法还是联合疗法，都在与乳腺癌作斗争中。但是，并非所有患者都会从这种疗法中受益。与马丁·布雷希比（Martin Brechbiel）博士一起，我们开发了一个标记为赫赛汀扫描的111英寸，它可以可视化HER2/NEU受体在体内和肿瘤中的分布。该药物在小鼠中进行了彻底评估，在第0阶段研究中已获得了对人的介绍的初步批准。与DDG合作，我们正在为临床中心的人体试验中生产该代理，以评估赫赛汀的生物分布和监测反应。这项研究将作为估算剂量剂量法的基础，用于使用放射性免疫疗法与螯合到赫赛汀的α发射剂，特别是在腹膜上的转移性疾病中。